Melanoma Diagnostics
Castle Biosciences Q1 Revenues Grow 18 Percent
The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.
Castle Biosciences Q4 Revenues Grow 45 Percent
The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.